Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
0.4875
+0.0083 (1.73%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Verrica Pharmaceuticals Stock Forecast
VRCA's stock price has decreased by -93.04% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Verrica Pharmaceuticals stock have an average target of 6.00, with a low estimate of 2.00 and a high estimate of 10. The average target predicts an increase of 1,130.77% from the current stock price of 0.49.
Analyst Consensus: Hold
* Price targets were last updated on Nov 5, 2024.
Analyst Ratings
The average analyst rating for Verrica Pharmaceuticals stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 8, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 12, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 6, 2024 |
Financial Forecast
Revenue This Year
17.22M
from 7.57M
Increased by 127.58%
Revenue Next Year
32.38M
from 17.22M
Increased by 88.06%
EPS This Year
-0.41
from -1.48
EPS Next Year
-0.29
from -0.41
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 26.3M | 52.5M | 126.0M | ||
| Avg | 17.2M | 32.4M | 55.0M | ||
| Low | 7.5M | 16.2M | 19.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 246.9% | 204.9% | 289.1% | ||
| Avg | 127.6% | 88.1% | 69.9% | ||
| Low | -0.6% | -5.8% | -41.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.25 | - | -0.09 | ||
| Avg | -0.41 | -0.29 | -0.09 | ||
| Low | -0.71 | -0.56 | -0.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.